



# Biofit

FOSTERING  
INNOVATION  
& TRANSFER

A 360° approach to source  
early-stage innovations in Life Sciences

## PROGRAMME

6<sup>th</sup>  
edition

& 28<sup>th</sup>  
29<sup>th</sup>  
NOVEMBER  
2017



Strasbourg  
europtimist

# Strasbourg


France

 #BioFIT  
@BIOFIT\_EVENT

Organised by:  **eurasanté**  
Invest for Success



 **Alsace  
BioValley**

With the support of:  **conectus**  
LIFE SCIENCES

# WELCOME TO BIOFIT 2017

*«Year after year, BioFIT has emerged as the leading partnering event in Europe to source early-stage innovations and collaborative research capacities in Life Sciences.*

*We are pleased to see the development of the event as a marketplace for pre-seed, seed and Series A investment in Life Sciences over recent years.*

*During this 6<sup>th</sup> edition of BioFIT, you will be more than 1,000 delegates from 30 countries representing large companies, medium-sized businesses, start-ups as well as tech transfer organisations, academics and investors. We look forward to seeing many high-potential collaborations generated during the convention.*

*Don't miss also this edition's conferences, with international high-level speakers, which present the perfect opportunity to gain insight and discover the latest industry trends.*

*Now it's time for us to let you take the control of what is your event. We wish you productive and enjoyable two days, with a variety of meetings and partnership opportunities.»*

**Etienne Vervaecke,**  
General Commissioner of BioFIT



**1,200**  
DELEGATES



**800**  
ORGANISATIONS



**30+**  
COUNTRIES  
REPRESENTED



**35+**  
ONE-TO-ONE MEETINGS  
PER PARTICIPANT  
OVER 2 DAYS



**800**  
LICENSING  
OPPORTUNITIES  
(in 2016)

**80**

speakers

**15**

conferences  
and roundtable  
discussions

**100**

exhibitors

# TABLE OF CONTENTS

The Sponsors .....	4
The Organisers.....	6
The Steering Committee .....	7

## ONE-TO-ONE MEETINGS

Partnering.....	8
Who will you meet?.....	9

## AGENDA

Day 1 .....	10
Day 2 .....	11

## CONFERENCES AND ROUNDTABLE DISCUSSIONS

PLENARY SESSION .....	13
TRACK 1 .....	14
New players involved in innovation in the health sector	
TRACK 2 .....	18
Nurturing and licensing early-stage assets	
TRACK 3.....	22
Bioentrepreneur's challenges at pre-seed, seed & Series A stages	

## HOSTED EVENTS

Open Data Challenge .....	25
R&D Dating for Animal Health and Innovation .....	26
Medalis Conference .....	28

## PRESENTATION SESSIONS

Start-up Slams .....	30
Start-up Slams' Agenda .....	32
Licensing Opportunity Presentations .....	34
Licensing Opportunity Presentations' Agenda.....	35

## EXHIBITION

Exhibitor List .....	38
Floor Plan .....	39

The Supporters & Partners .....	67
---------------------------------	----

# THE SPONSORS

## GOLD SPONSOR



## BRONZE SPONSORS



## CONTRIBUTING SPONSORS




## INSTITUTIONAL PARTNERS



# Empowering Life

Sanofi.com

SANOFI  Empowering Life



*Extraordinary medicine  
requires extraordinary science.*

That's why we are committed to discovering and developing personalised medicines and targeted diagnostic tests to help people live better, longer lives.



# THE ORGANISERS

## EURASANTÉ

Eurasanté is an incubator, a technology transfer facilitator and a leading cluster in the fields of biotech, nutrition and healthcare in the Northern France region. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects.

The regional network includes more than 1,000 companies working in Life Sciences and Healthcare. It benefits from an exceptional location in the heart of Europe (near Paris, London and Brussels). The Life Sciences sector in the Northern France region gathers a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, more than 150 companies and 50 laboratories.

In addition, Eurasanté organises 4 international partnering events annually, which aim to increase and improve interactions between academia and industry and encourage additional innovative sector collaborations: BioFIT, MedFIT, NutrEvent and AgeingFit.

[www.lille.eurasante.com](http://www.lille.eurasante.com) @Eurasante



## THE NHL CLUSTER

The Nutrition Health Longevity (NHL) Cluster is a dynamic network focusing on the main issues at the crossroads of health, biotechnology and nutrition.

The NHL Cluster aims to federate public and private partners around R&D projects, which lead to innovative products in the fields of nutrition and health.

The NHL Cluster's activity is centred around the prevention and treatment of life-style related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative and inflammatory bowel diseases. Its objective is to gather and support players from the health and food sectors in the design, the development and financing of their future products and processes.

[www.nhl-cluster.com](http://www.nhl-cluster.com) @PoleNSL



## ALSACE BIOVALLEY

As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimise any R&D development or business project in Europe, both in drug development and medical technologies. Located in Eastern France, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies or academics interested in new projects and partnerships in Europe to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or set up and locate in Eastern France. Alsace BioValley has also agreements with BioWin (Wallonia), CQDM (Quebec), JBA (Japan Bioindustry Association), Biopro (Germany) and Basel Area (Switzerland).

[www.alsace-biovalley.com](http://www.alsace-biovalley.com) @AlsaceBiovalley



# THE STEERING COMMITTEE

## PHARMA, BIOTECH



**Cédric Barriere**

DIRECTOR, EXTERNAL INNOVATION  
ONCOLOGY, EXTERNAL SCIENCE  
AND PARTNERING, **SANOFI** [FR]



**Maria Bobadilla**

SENIOR DIRECTOR, EXTENDING  
INNOVATION NETWORK,  
**ROCHE** [CH]



**Adrian Carter**

CORPORATE VICE PRESIDENT AND  
GLOBAL HEAD OF DISCOVERY  
RESEARCH COORDINATION,  
**BOEHRINGER INGELHEIM** [DE]



**Sami Chtourou**

DIRECTOR OF TECHNOLOGY  
PLATFORMS AND INNOVATION,  
**LFB** [FR]



**Florence Dal Degan**

R&D INNOVATION SOURCING  
DIRECTOR, **NOVO NORDISK** [DK]



**Guy Helin**

CEO, **SYNGULON** [BE]



**Stephan Lensky**

CHIEF OPERATING AND CHIEF  
BUSINESS OFFICE, **EPIMAB**  
**BIOTHERAPEUTICS** [CN]



**Sabrina Lesage**

STRATEGIC ALLIANCES MANAGER,  
**PFIZER** [FR]



**Pascal Raoul**

SCIENTIFIC AND INNOVATION  
DIRECTOR, **CEVA** [FR]



**Frédéric Scaerou**

DIRECTOR, SCIENTIFIC  
AFFAIRS ONCOLOGY,  
**IPSEN INNOVATION** [FR]



**Nadine Weisslinger-Darmon**

MEDICAL DIRECTOR SPECIALTY  
PRODUCTS, CLINICAL RESEARCH  
AND ACADEMIC ALLIANCES, **GSK** [FR]

## ACADEMIA, TTOs



**Hervé Ansanay**

OPERATIONS DIRECTOR,  
**SATT AXLR** [FR]



**Garold Breit**

DIRECTOR, TECHNOLOGY  
BUSINESS DEVELOPMENT,  
**CITY OF CHARLESTON** [USA]



**Nicolas Carboni**

PRESIDENT, **SATT CONECTUS**  
**ALSACE** [FR]



**Jean-Luc Chagnaud**

HEALTHCARE BUSINESS  
DEVELOPMENT MANAGER  
& INTELLECTUAL PROPERTY  
MANAGER, **AQUITAINE SCIENCE**  
**TRANSFERT** [FR]



**Lilla Farkas**

HEAD OF THE OFFICE OF THE  
MANAGING DIRECTOR, RESEARCH  
COORDINATOR, **MPI-CBG**,  
**MAX PLANCK INSTITUTE OF**  
**MOLECULAR CELL BIOLOGY AND**  
**GENETICS** [DE]



**Matthieu Fisichella**

LIFE SCIENCES EXPERT,  
**SATT NORD** [FR]



**Esther Lange**

INDUSTRY LIAISON MANAGER,  
**ASCENION** [DE]

## ASSOCIATIONS, CLUSTERS, INVESTORS & LAW FIRMS



**Claude-Alain Cudennec**

GENERAL DIRECTOR, **AFSSI -**  
**THE FRENCH ASSOCIATION OF**  
**OUTSOURCING AND INNOVATIVE**  
**COMPANIES** [FR]



**Barbara Freischem**

MANAGING DIRECTOR, **EBE -**  
**EUROPEAN BIOPHARMACEUTICAL**  
**ENTERPRISES** [BE]



**Jean-Louis Hunault**

PRESIDENT, **SIMV - THE FRENCH**  
**ASSOCIATION OF THE ANIMAL**  
**HEALTH INDUSTRY** [FR]



**Sara Nunez-Garcia**

PRINCIPAL,  
**SOFINNOVA PARTNERS** [FR]



**Marco Pintore**

GENERAL MANAGER,  
**ALSACE BIOVALLEY** [FR]



**Christian Policard**

MEMBER OF THE BOARD,  
CHAIRMAN OF THE BUSINESS  
DEVELOPMENT SUB-COMMITTEE,  
**FRANCE BIOTECH** [FR]



**Emilie Royere**

DIRECTOR, **EUROBIOMED** [FR]



**Cécile Theard-Jallu**

PARTNER ATTORNEY, **DE GAULLE**  
**FLEURANCE & ASSOCIÉS** [FR]




**Etienne Vervaecke**

GENERAL MANAGER,  
**EURASANTE & NHL CLUSTER** [FR]

# PARTNERING

*48 hours to meet your future project partners,  
accelerate innovation and get financed*



**30%** TTOs, Research institutions, Academics



**20%** Pharma & Diagnostic companies



**20%** Emerging Biotech companies



**15%** Preclinical CROs



**10%** Pre-seed, seed and Series A investors



**5%** Professional services, consulting and law firms

The partnering platform at BioFIT is powered by **partneringONE®**

a service of **EBD GROUP**

**Any question? The BioFIT team at the Partnering desk  
(Exhibition hall) will be happy to assist you.**

CHECK THE FLOOR PLAN PAGE 39



# WHO WILL YOU MEET?

**1,200 +**  
**key actors**

**INCLUDING:**

Astellas Pharma, Basilea Pharmaceutica International, Bayer, Bayer Animal Health, Boehringer Ingelheim, Boehringer Ingelheim Animal Health, Ceva, Daiichi Sankyo, Evotec, Ferring Pharmaceuticals, GSK - GlaxoSmithKline, Ipsen Innovation, Johnson & Johnson Innovation, Kissei America, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Laboratorios Rubio, LFB, Lilly, Merck, MSD, MSD Animal Health, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Syngulon, Takeda, TiGenix, Trianni, Vetoquinol, Virbac, Zoetis, Ascension, CNRS, EMBLEM, FIST, Imperial Innovations, LifeArc, Max Planck Institute, SATT Network, University of Birmingham, University of Cambridge, VIB, Broadview Ventures, Edmond de Rothschild Investment, Fund+, High-Tech Gründerfonds, Merck Ventures, Novartis Venture Fund, Sofinnova Partners, Thiel Capital, Truffle Capital, TVM Capital

**From 30 countries**  
**around the world**

**INCLUDING:**



Austria



Belgium



Canada



China



Czech Republic



Denmark



Finland



France



Germany



Greece



Iceland



Ireland



Israel



Italy



Japan



Lithuania



Malaysia



Netherlands



Norway



Poland



Portugal



Singapore



South Korea



Spain



Sweden



Switzerland



Ukraine









United Kingdom



United States

# AGENDA DAY ONE

**Tuesday 28<sup>th</sup> November 2017**

8.30 am 9.30 am	WELCOME COFFEE				
	Conferences and roundtable discussions	Presentation sessions	Hosted Event  Centre de recherche du médicament Drug Discovery Centre	Partnering	
9.30 am 11.00 am	<b>MADRID 4 ROOM</b> Shared risk or competition for emerging assets: How can we optimise pharma-VC relationships?	<b>MADRID 3 ROOM</b> How can collaborations in rare diseases be an asset in a highly competitive and fast moving market?	<b>INNOV AREA</b> <b>EXHIBITION HALL</b>  Licensing Opportunity Presentations  Cancerology Osteo-Articular	<b>ROME 5 ROOM</b>  Translational research at Medalis: From lab to biotech	 <b>Biofit</b> <small>ACADEMIC PHARMACEUTICAL &amp; BIOTECHNOLOGY</small>  One-to-one meetings  &   <b>BIMV</b> <small>R&amp;D DATING FOR ANIMAL HEALTH AND INNOVATION</small>  R&D dating for animal health and innovation
11.00 am 11.30 am	NETWORKING BREAK				
11.30 am 1.00 pm	<b>PLENARY SESSION</b> How can we overcome the shortage of bioentrepreneurs in Europe? <b>CURIE ROOM - 1<sup>st</sup> FLOOR</b>				
1.00 pm 2.30 pm	LUNCH				
2.30 pm 4.00 pm	<b>MADRID 4 ROOM</b> Exploring the growing relationship between pharma, digital health companies and data providers	<b>MADRID 3 ROOM</b> Assessing the opportunity for licensing early-stage projects	<b>INNOV AREA</b> <b>EXHIBITION HALL</b> Start-up Slams Vascular / Metabolic Op2Lysis   Emosis   Cardior Pharmaceuticals   AptamiR Therapeutics Vaccinology / Virology ViRelieve   Vaxinano   ParImmune	<b>ROME 5 ROOM</b>  Early projects, early opportunity: Find your match	 <b>Biofit</b> <small>ACADEMIC PHARMACEUTICAL &amp; BIOTECHNOLOGY</small>  One-to-one meetings  &
4.00 pm 4.30 pm	NETWORKING BREAK				
4.30 pm 6.00 pm	<b>MADRID 4 ROOM</b> How are focused therapeutic funds becoming increasingly important at pre-seed, seed and series A stages?	<b>MADRID 3 ROOM</b> <b>Workshop:</b>  A closer look at early-stage collaborations in the UK	<b>INNOV AREA</b> <b>EXHIBITION HALL</b>  Licensing Opportunity Presentations  Cancerology Osteo-Articular	<b>ROME 5 ROOM</b>  Nature and nurture of an Academic drug discovery Centre	 <b>BIMV</b> <small>R&amp;D DATING FOR ANIMAL HEALTH AND INNOVATION</small>  R&D dating for animal health and innovation
6.30 pm	BIOPARTY				<b>ETOILE ROOM 1<sup>st</sup> FLOOR</b>

**Wednesday 29<sup>th</sup> November 2017**

9.00 gm

## Conferences and roundtable discussions

## Presentation sessions

## Partnering

MADRID 4 ROOM

MADRID 3 ROOM

INNOV AREA

EXHIBITION HALL

## How to keep the founding scientists committed?

How are collaborations key to improve innovation in metabolic diseases?

**Start-up Slams**  
Oncology/Immuno-  
Onco  
STipe Therapeutics |  
Theranovir | Elthera  
| Chromalys

## NETWORKING BREAK

MADRID 4 ROOM

MADRID 3 ROOM

INNOV AREA

EXHIBITION HALL

Where will  
European pre-  
seed, seed and  
Series A investment  
go in 2018?

How can  
animal and  
human innovation  
/ applications be  
mutually beneficial?

Licensing  
Opportunity  
Presentations

Neurology  
Vascular/Metabolic

## LUNCH

MADRID 4 ROOM

MADRID 3 ROOM

INNOV AREA

EXHIBITION HALL

Are venture philanthropy and trusts emerging in the initial stages of funding?

How can TTOs increase their role in the early development of spin-offs?

**Start-up Slams**  
Research tools/  
Therapeutic delivery  
Mecachips | DyNAbind  
| SimplicityBio | Renovos  
Ageing / Pain  
Innopain  
| PRAGMA Therapeutics  
| Reminiscences

MADRID 4 ROOM

INNOV AREA

EXHIBITION HALL

How can we define a mutually beneficial collaboration between an academic institution and a resulting spin-off?

Award ceremony  
of the most  
innovative  
start-up

4.00 pm

4.30 pm

4.30 pm

5.00  $\mu\text{m}$

6.00 pm

## CLOSING COFFEE BREAK

- Track 1: New players involved in innovation in the health sector
- Track 2: Nurturing and licensing early-stage assets
- Track 3: Bioentrepreneurs' challenges at pre-seed, seed and Series A stages

 **Biofit** FOSTERS  
INNOVATION  
& TRANSFER

One-to-one  
meetings

&amp;



**SIMV**  
R&D DATING FOR  
ANIMAL HEALTH  
AND INNOVATION

R&D dating for  
animal health an  
innovation

FOR MANY, AN ACTIVE LIFE  
STOPS FAR TOO EARLY | OUR SCIENTISTS  
WON'T ACCEPT THAT



By 2050 the world's population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That's why we're seeking to help people stay healthier and more active in later life, be it through more targeted treatments for cancer and cardiovascular conditions,

solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn't stop at 60 – not by any means. To find out how our innovations are helping to change lives for the better, visit [www.bayer.com/ari1901](http://www.bayer.com/ari1901).



Science For A Better Life

*Johnson & Johnson* INNOVATION

BECAUSE A GREAT IDEA  
CAN COME FROM ANYWHERE

MAKE *the* CONNECTION

**Johnson & Johnson Innovation Centres**

A flexible approach to advancing early-stage innovation

Johnson & Johnson Innovation seeks to find the best science and technology partners, no matter where they are, to solve the greatest unmet needs of our time. Positioned at the heart of the world's most creative science hubs, we take a collaborative approach to partnering to advance early-stage innovation.

The next breakthrough idea can come from anywhere. Maybe it will come from you.  
Together we can transform ideas into healthcare solutions that change lives.

 @jnjinnoation

[www.jnjinnoation.com](http://www.jnjinnoation.com)



©Johnson & Johnson Innovation LLC 2017.

# CONFERENCES AND ROUNDTABLE DISCUSSIONS

---

**28<sup>th</sup> Nov.** 11.30 am - 1.00 pm | CURIE ROOM

---



**MODERATOR**

**John Hodgson**

DATA EDITOR, **INFORMA**

## ***How can we overcome the shortage of bioentrepreneurs in Europe?***

Europe is currently benefiting from a unique level of academic research and access to equity investment has also improved. Despite this, Europe is still lacking bioentrepreneurs. How can we attract entrepreneurs in Life Sciences? How to convince talented scientists to become entrepreneurs? Can the support from technology transfer offices, incubators and early investors provide sufficient mentorship and a wide enough network?

**David Wehner**

MANAGING DIRECTOR,  
**VENNEOS**

**Toby Reid**

MANAGING DIRECTOR,  
**BIOCITY**

**Alain Wagner**

RESEARCH DIRECTOR,  
**CNRS**

**Valentin Lubbe**

PROGRAM MANAGER,  
**NORDIC MENTOR NETWORK  
FOR ENTREPRENEURSHIP**

**Dick Hoogenberg**

PARTNER, **EY**

Share your opinion on Twitter:



**#BioFIT**  
**@BIOFIT\_EVENT**

# TRACK 1

## **New players involved in innovation in the health sector**

Big data and health IT companies provide key expertise to potentially increase efficiency in the discovery, preclinical and clinical stages of development. What will their position and involvement be in the therapeutic innovation chain: Will they participate or lead? Examples of collaborations between biotech, pharma, IT companies and academic research will be highlighted. However, these new players don't only originate from the big data sector, they also come from various areas such as animal health or e-health.

---

**28<sup>th</sup> Nov. 9.30 - 11.00 am | SALON MADRID 3 ROOM**

---



**MODERATOR**

**Wendy White**

CHAIR, GLOBAL GENES 

### **HOW CAN COLLABORATIONS IN RARE DISEASES BE AN ASSET IN A HIGHLY COMPETITIVE AND FAST MOVING MARKET?**

**Fiona Nielsen**

CEO, REPOSITIVE 

**Ward Capoen**

SENIOR ANALYST,  
V-BIO VENTURES 

**Olaf Ritzeler**

SENIOR DIRECTOR, EXTERNAL  
INNOVATION, RARE DISEASES,  
SANOFI 

**Yann Hérault**

DIRECTOR,  
INSTITUT CLINIQUE  
DE LA SOURIS 

How does the specific context of rare diseases (including fast-track status, low prevalence score) work in favour of long-lasting and shared partnerships between start-ups, pharma, academia, regulatory bodies and patient organisations?



**MODERATOR**

**Elsa Sotiriadis**

CHIEF FUTURIST  
& DIRECTOR, SOSV

## **EXPLORING THE GROWING RELATIONSHIP BETWEEN PHARMA, DIGITAL HEALTH COMPANIES AND DATA PROVIDERS**

**Seamus Browne**

HEAD OF INDUSTRY  
PARTNERSHIPS, RCSI

**Karlheinz Schmelig**

MANAGING PARTNER,  
CREATHOR VENTURES

**Andrew Fried**

LIFE SCIENCES EUROPE  
DIRECTOR, IBM

**Amer Fasihi**

FOUNDER  
CAROS CONNECT

How can the availability of huge amounts of data, computational tools that can effectively analyse this data, and targeting therapeutics to specific populations can make this relationship grow faster for the benefit of innovation? With the right tools, do R&D professionals have the ability to rapidly mine data from the literature, regulatory documents, clinical trial data, electronic health records and other patient-centric information to help innovation move forward? To what extent will the growing place of big data companies offer them a leader role in the projects?



**MODERATOR**

**Farzad  
Abdi-Dezfuli**

PARTNER, SARSIA SEED  
MANAGEMENT AS

## **HOW CAN COLLABORATIONS KEY TO IMPROVE INNOVATION IN METABOLIC DISEASES?**

**Grit Zahn**

HEAD OF RESEARCH,  
ETERNYGEN

**Philippe Froguel**

PROFESSOR OF GENOMIC MEDICINE,  
IMPERIAL COLLEGE LONDON,  
PROFESSOR OF ENDOCRINOLOGY,  
LILLE UNIVERSITY HOSPITAL

**Florence Dal Degan**

R&D INNOVATION SOURCING  
DIRECTOR, NOVO NORDISK

Examples of successful collaborations to improve innovation in metabolic diseases. Through the presentation of several case studies: We will discuss how collaborations are key to improving innovation in metabolic diseases. This session will feature one collaborative model, one innovative start-up project, and a successful academia/pharma collaboration.



**MODERATOR**

**Pascal Breton**

PRESIDENT & CEO,  
VITAMFERO 

## **HOW CAN ANIMAL AND HUMAN INNOVATION / APPLICATIONS BE MUTUALLY BENEFICIAL?**

We will address innovation opportunities and pitfalls to be avoided when engaging in collaborations between human health players and animal health actors. Which are the conditions to be gathered to make innovation happen? Which types of collaborations can be put in place? What are the successful examples? What are the limits to these collaborations?

**Rudiger Raue**

ASSOCIATE DIRECTOR  
EXTERNAL INNOVATION,  
ZOETIS 

**Peter Opdam**

DIRECTOR, BUSINESS  
DEVELOPMENT EUROPE,  
MSD ANIMAL HEALTH 

**Isabel Fidalgo Carvalho**

CEO,  
EQUIGERMINAL 

**Pascal Boireau**

COORDINATOR,  
DIM 1HEALTH 






## Working together for better health

At Boehringer Ingelheim we believe in forming durable partnerships to develop innovative new medicines in areas of high unmet need. Our relationships range from discovery research, development and technology collaborations to clinical and commercial partnerships and full-scale, long-term strategic alliances.

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

We invite you to find out more about partnering with us by visiting  
<http://partnering.boehringer-ingelheim.com>

[www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)



## INVENT WITH US

### MSD BUSINESS DEVELOPMENT & LICENSING

MSD is inventing because the world still needs cures for cancer, Alzheimer's disease, HIV, and so many other causes of widespread suffering.

We believe that building strong partnerships is critical to solving these challenging diseases — to help people go on, unburdened, to experience, create and live their best lives.

*Together we can invent for life.*

Learn more at [msd.com/licensing](http://msd.com/licensing).



MSD is known as Merck in the United States and Canada.

Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. 9-17

# TRACK 2

## ***Nurturing and licensing early-stage assets***

Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. This subject will focus on assessing opportunities in licensing early-stage projects, discussing the mentoring role of TTOs and exploring scientists' commitment. It aims to underline the difficulties for maturing early-stage assets. How can we transform science into business more frequently and efficiently?

---

**28<sup>th</sup> Nov. 2.30 - 4.00 pm | SALON MADRID 3 ROOM**

---



**MODERATOR**

**Marta Catarino**

TECH TRANSFER  
DIRECTOR, **TECMINHO** 🇵🇹

### **ASSESSING THE OPPORTUNITY FOR LICENSING EARLY-STAGE PROJECTS**

What factors should be considered whether to out-license a technology or develop it towards a start-up? At what stage should the decision be made whether to out-license or to spin out? How does the decision whether to license or spin-out impact the commercialisation or 'transfer' strategy? What are the assets that an academic could think about when considering whether to spin out?

**Pascal Neuville**

CEO, **DOMAIN  
THERAPEUTICS** 🇫🇷

**Johan Cardoen**

MANAGING DIRECTOR,  
**VIB** 🇧🇪

**Georgia Gliki**

SENIOR BUSINESS  
MANAGER TECHNOLOGY  
TRANSFER, **LIFEARC** 🇬🇧

**Klaus Mendla**

GLOBAL HEAD,  
CNS BD & LICENSING,  
**BOEHRINGER INGELHEIM** 🇩🇪

**Beat Steffen**

PRINCIPAL,  
**NOVARTIS VENTURE FUND** 🇨🇭



MODERATOR

**Eric Halioua**

CEO, PDC\*LINE PHARMA

## **How to keep the founding scientists committed?**

To what extent should the scientist manage the future of the spin off? What is their role within a new professional management team? Can we impose on a scientist the role of being a CEO? What are the pro's and con's of the Professor becoming the CEO of his own spin-off? What needs to be considered when forming a company and what does that mean for the founding scientist?

**Davidson Ateh**

CO-FOUNDER & CEO,  
BIOMOTI

**Barbara Domayne-Hayman**

CHAIR,  
PURIDIFY

**Egil Hulgaard**

SENIOR EXECUTIVE BUSINESS  
DEVELOPMENT OFFICER,  
TECHNICAL UNIVERSITY OF  
DENMARK

**Sascha Berger**

PRINCIPAL, TVM LIFE  
SCIENCE MANAGEMENT

**Tony Hickson**

MANAGING DIRECTOR,  
IMPERIAL INNOVATIONS



MODERATOR

**David Coleman**

HEAD OF SPIN-OUT COMPANIES,  
ALTA INNOVATIONS

## **How can TTOS increase their role in the early development of spin-offs?**

Building the management team and completing initial financing rounds are key moments in the emergence of a new company. To what degree are TTOs involved in these two aspects of the project? How do they help newly-funded companies interact with their industrial and financial partners?

**Tami Raz**

CEO, HADASIT, TECHNOLOGY  
TRANSFER COMPANY OF HADASSAH  
MEDICAL ORGANIZATION

**Duncan Holmes**

EUROPEAN HEAD, DISCOVERY  
PARTNERSHIPS WITH ACADEMIA,  
GLAXOSMITHKLINE

**Mike Karim**

CEO, OXFORD ENDOVASCULAR

**Serge Pampfer**

MANAGING DIRECTOR,  
WBC INCUBATOR



**MODERATOR**

**John Mack**

PHARMA PUNDIT &  
PUBLISHER, PHARMA  
MARKETING NEWS 

**Axel Polack**

GENERAL PARTNER, JOINT  
POLISH INVESTMENT FUND 

**Tamer Mohamed**

CEO, ASPECT BIOSYSTEMS 

**Miguel Mulet**

DIRECTOR OF STRATEGY &  
CORPORATE DEVELOPMENT,  
TIGENIX 

**Timothy Luker**

SENIOR DIRECTOR, EMERGING  
TECHNOLOGY & INNOVATION,  
BUSINESS DEVELOPMENT,  
ELI LILLY 

## **HOW CAN WE DEFINE A MUTUALLY BENEFICIAL COLLABORATION BETWEEN AN ACADEMIC INSTITUTION AND A RESULTING SPIN-OFF?**

How can we nurture a long-lasting collaboration between a university and its spin-offs? How do universities continue to provide the start-up with the support required? After the initial licensing deal, how often do academic institutions supply start-ups with additional licensing opportunities?



---

**28<sup>th</sup> Nov. 4.30 - 6.00 pm | SALON MADRID 3 ROOM**

---

**MODERATOR****John Harris**

CEO, OBN

## **A CLOSER LOOK AT EARLY-STAGE COLLABORATIONS IN THE UK**

**Harry Destecroix**

CEO, ZIYO

**Oliver Sexton**INVESTMENT MANAGER,  
RAINBOW SEED FUND **Shawn Manning**CEO,  
AKESIOS ASSOCIATES **Mak Khan**BUSINESS DEVELOPMENT &  
TRANSACTIONS MANAGER,  
CELL & GENE CATAPULT **Vibhuti Patel**TRANSLATIONAL RESEARCH MANAGER  
BIOSCIENCE IMPACT TEAM,  
UNIVERSITY OF CAMBRIDGE 

UK enjoys a very dynamic life sciences sector ensuring synergies between academic excellence, start-up pools and industrials.

Several illustrations of the dynamism of the Life Sciences industry in the UK will be highlighted during this workshop:

- ♦ Successful examples of collaborations UK academia/ European Industry or UK start-up/ European industry
- ♦ Cross border M&A to expand internationally
- ♦ Venture capital & early-stage funds in the UK

# TRACK 3

## Bioentrepreneurs' challenges at pre-seed, seed & Series A stages

The right mindset, a solid presentation and business model are not the only requirements that bioentrepreneurs must fulfil at pre-seed, seed and Series A stages. What have been the expectations of project maturity from investors in 2017? How often are new types of early-stage investors involved in financing rounds (including philanthropic and specialised ventures)? How does the angels/seed investors relationship work? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?

---

28<sup>th</sup> Nov. 9.30 - 11.00 am | SALON MADRID 4 ROOM

---



MODERATOR

**Michael Nowak**

MANAGING PARTNER,  
NOWAK VENTURES 

### SHARED RISK OR COMPETITION FOR EMERGING ASSETS: *How can we optimise Pharma-VC relationships?*

**Lucas de Breed**

DIRECTOR, INKEP CAPITAL 

**Detlev Mennerich**

INVESTMENT MANAGER,  
BOEHRINGER INGELHEIM VENTURES 

**Timothy Luker**

SENIOR DIRECTOR, EMERGING TECHNOLOGY & INNOVATION, BUSINESS DEVELOPMENT, ELI LILLY 

**Nathalie ter Wengel**

EUROPEAN HEAD EXTERNAL R&D AND INNOVATION, PFIZER 

**Frédéric Legros**

COO, DYNACURE 

What are the consequences of the increasing interactions and partnerships between pharma and VCs at the initial stages of pre-seed, seed and Series A? What is the role of Corporate VCs in this context?



**MODERATOR**

**Fabrice Arousseau**

CEO, PPRS RESEARCH 

## **HOW ARE FOCUSED THERAPEUTIC FUNDS BECOMING INCREASINGLY IMPORTANT AT PRE-SEED, SEED AND SERIES A STAGES?**

What do these therapeutic funds bring to the companies and community of investors in terms of quality of expertise and specific network opportunities? Does the presence of focused therapeutic funding in the early stages ease the co-investment of more generalist funds?

**James Peyer**

MANAGING PARTNER,  
APOLLO VENTURES 

**Christian Tidona**

MANAGING PARTNER & FOUNDER,  
BIOMED X 

**Michael Midmer**

CEO, ZUCARA THERAPEUTICS 

**Jakob Loven**

PARTNER, NEXTECH INVEST 

**Philippe Pouletty**

FOUNDER, TRUFFLE CAPITAL 



**MODERATOR**

**Evelyne Nguyen**

CEO, ANM PARTNERS 

## **WHERE WILL EUROPEAN PRE-SEED, SEED AND SERIES A INVESTMENT GO IN 2018?**

What is the state of pre-seed, seed and Series A funding in Europe? What are the investment opportunities to watch for in 2018? What are the models, therapeutic area or innovative techniques to highlight when looking for financing? Can we expect a rise in pre-seed and seed money in Europe for 2018? What are the expectations for project maturity from investors in 2017?

**Holger Reithinger**

GENERAL PARTNER, FORBION  
CAPITAL PARTNERS 

**Hakan Goker**

SENIOR INVESTMENT DIRECTOR,  
MERCK VENTURES 

**Frank Hensel**

SENIOR INVESTMENT MANAGER,  
HIGH-TECH GRÜNDERFONDS 

**Sofia Ioannidou**

INVESTMENT DIRECTOR,  
EDMOND DE ROTHSCHILD  
INVESTMENT PARTNERS 



**MODERATOR**

**Paul Hermant**

PARTNER, BIRD & BIRD 

## **ARE VENTURE PHILANTHROPY AND TRUST EMERGING IN THE INITIAL STAGES OF FUNDING?**

**Christopher de Souza**

DIRECTOR,  
BROADVIEW VENTURES 

**Andreas Schmidt**

CO-FOUNDER,  
AYOXXA BIOSYSTEMS 

**Chris Greenwood**

HEAD OF INVESTOR  
RELATIONS, ESPERARE 

**Kayar Raghavan**

ANGEL INVESTOR 

What non-profit and non-dilutive sources of funding are available? Are these new actors equally active at maturation, pre-seed and seed stages? What potential leverage to accessing grants and other non-dilutive sources of funding does venture philanthropy offer to newly founded companies?



## **INNOVATIVE COMPANY IN TREATMENT AND DIAGNOSIS OF METABOLIC & INFLAMMATORY DISEASES**

**Connect together**



[www.genfit.com](http://www.genfit.com)



[contact@genfit.com](mailto:contact@genfit.com)




GENFIT



[genfit\\_pharma](#)



HOSTED EVENT BY  **Biofit**



## Challenge OPEN DATA

The Open Data Challenge is a call for projects that encourages open innovation initiatives between companies and public institutions facing digital challenges and SMEs which provide innovative technologies. Launched during summer 2017, the first phase of this project ended in September 2017 with the selection of three companies for their innovative solutions aimed at resolving the EFS's (French Blood Agency) blood forecasting needs.

The selected companies competing for the challenge are Kaduceo, Open DataSoft and Open Health.



Award Ceremony | **28<sup>th</sup> Nov. 5.30 pm** | BOOTH D7 (Exhibition Hall)

*«EFS' participation at the Open Data Challenge was obvious considering the interesting theme and regarding the opportunity to collaborate with qualified start-ups. This initiative, centred on Open Data will allow us to enhance our ability to adapt to upcoming evolutions and therefore, be as efficient as possible.»*

Eric Resch, Haemovigilance and distribution officer, **EFS**

*«Through our Digital Launch Pad Program, launched 2 years ago, we have helped hundreds of companies to develop their business activities. An increasing number of our clients work in the health sector and we are providing them with the necessary data storage services. We are delighted to share the type of expertise at the Open Data Challenge.»*

Guillaume Fillière, Digital Launchpad Programme Manager, **OVH**

Organised by:



In collaboration with:



In partnership with:



Financed by:





BioFIT hosts the 3<sup>rd</sup> edition of the “R&D dating for Animal Health and Innovation”, initiated by the French association for the animal health industry (SIMV), on 28<sup>th</sup> and 29<sup>th</sup> November 2017 in Strasbourg.

Today, public-private and private-private partnerships are thought to be the needed leverage for innovation. Hence, the SIMV (the French association for the animal health industry) launched the “R&D dating for Animal Health and Innovation” which aims at initiating high-level exchanges between the research departments of the veterinary medicine and diagnostics industry and public research, as well as biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

---

**29<sup>th</sup> Nov. 11.00 am - 12.30 pm | SALON MADRID 3 ROOM**

---

## **How can animal and human innovation/applications be mutually beneficial?**

We will address innovation opportunities and pitfalls to be avoided when engaging in collaborations between human health players and animal health actors. Which are the conditions to be gathered to make innovation happen? Which types of collaborations can be put in place? What are the successful examples? What are the limits to these collaborations?

**> See details page 16**

**MEET SIMV AT BOOTH C13**

Organised by:





The OneHealth Company

**FULL-VET CRO**  
**for Human & Pets Health**

**Comparative medicine studies of pets  
with natural diseases for the Biotech/  
Pharma industry**

*Dogs & Cats with natural cancer or age-  
related diseases as predictive models of  
human diseases*

**Pilot & Pivotal studies with pets for  
the Vet industry**

*Pets suffering from age-related diseases*

Web: <http://www.oncovet-clinical-research.com/>  
Contact: [mdubruque@oncovet-clinical-research.com](mailto:mdubruque@oncovet-clinical-research.com)



LEARNING  
UNDERSTANDING  
TREATING

**TOGETHER**



# HOSTED EVENT BY **Biofit**



The Medalis drug research centre is a «Laboratory of Excellence» (Labex) created in July 2011 as part of the French «Investments for the Future» programme. It is a member of «Initiatives of excellence» (IDEX) in the University of Strasbourg. Its aim is to develop innovative drugs for the treatment of cancer or inflammation.

Medalis' strengths:

- ◆ A unique network of 200 researchers and PhDs from 11 research teams focused on chemistry and biology whose excellency has been certified by the national «Agency for Evaluation of Research and Universities», currently «Haut Conseil de l'Évaluation de la Recherche et de l'Enseignement Supérieur».
- ◆ State-of-the-art scientific equipment, such as platforms dedicated to virtual and microfluidic screening.
- ◆ A stimulating environment: Medalis is based in the heart of Europe, in Strasbourg, where the research institutes are internationally renowned for their achievements in the fields of pharmacology and biotechnology.

Medalis researchers have access to a highly competitive research environment provided by Strasbourg University and national research institutions like CNRS or INSERM. Moreover, Strasbourg University was awarded for the excellence of its supported projects (including Medalis) and has received an «Initiative of Excellence» funding from the French Investment for the Future Programme.

# LABEX MEDALIS CONFERENCE PROGRAMME

## SESSION 1

### Translational research at Medalis: From lab to biotech

**28<sup>th</sup> Nov. 9.30 - 11.00 am | ROME 5 ROOM**

**ImmuPharma, a successful pioneer in academic private intimate collaboration** [Sylviane MULLER, Laboratory of Immunology and Therapeutic Chemistry UPR3572 CNRS, Director; Robert Zimmze, CEO ImmuPharma].

**From the molecular dissection of signalling receptor transmembrane domains interaction in cancer** [Dominique Bagnard, The Microenvironmental Niche in tumorigenesis and targeted therapy INSERM U1109, Group Head] to **PeptiMimesis**

**Pharma** [Marjorie Sidhoum, CEO].

**From innovation in click chemistry** [Alain Wagner, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-Unistra, Group Head] to **Syndivia** [Sasha Koniev, CEO].

**From the development of a molecular tool predicting cancer drug efficacy**, [Justine Fritz, Former PhD in Dominique Bagnard group, MN3T lab] to **Adaptherapy** [Bertrand Loubaton, CEO].

## SESSION 2

### Early projects, early opportunity: Find your match

**28<sup>th</sup> Nov. 2.30 - 4.00 pm | ROME 5 ROOM**

**Moderator:** Jean-Christophe Peter [Scientific Manager, Labex Medalis]

**Development of a PPI inhibitor of the CDK4/cyclin D complex for cancer treatment** [Frédéric Bihel, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

**Preclinical validation of the therapeutic potential of MTP-PlexA1 in demyelination disease** [Fabien Biname, The Microenvironmental Niche in tumorigenesis and targeted therapy INSERM U1109].

**Fluorospexin and Pain** [Dominique Bonnet, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra, And Frédéric Simonin, GPCR, Pain and Inflammation, UMR 7242 CNRS-Unistra].

**Peptide P140 and asthma: Preclinical evaluation in relevant mouse models** [Nelly Frossard,

Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

**Neutraligands of CXCL12** [Marcel Hibert, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

**Nanostructured Carriers for Intelligent siRNA co-delivery with anticancer drugs**

[Antoine Kichler, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-Unistra].

**A global and rational approach to PPI modulation** [Didier Rognan, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

**MicroOmics: Deciphering cancer heterogeneity at the single cell multi-omic level** [Sylvain Ursuegui, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-Unistra].

## SESSION 3

### Nature and nurture of an academic drug discovery centre

**28<sup>th</sup> Nov. 4.30 - 6.00 pm | ROME 5 ROOM**

#### ROUND TABLE:

**Moderator:** Jean-Christophe Peter, Scientific Manager, Labex Medalis

- ◆ How developing a continuing research effort out of the box?
- ◆ How educating researchers at the interface of chemistry and biology?
- ◆ How involving industrial partners?
- ◆ The role of corporate sponsorship in such initiatives?

[Pierre Efekhari, INOVIEM Scientifique - Serge Potier, University of Strasbourg - Jean Gagneux, CiRFC Foundation - Marcel Hibert, Faculty of Pharmacy - Stéphane Jenn, NOVALIX - Pascal Neuville, Domain Therapeutics].

# START-UP SLAMS

The Start-up Slams are presented by entrepreneurs who have created an innovative company (less than 5-year-old or to be created). During the presentations, the selected candidates will present their project to potential partners and investors who could support their company and receive feedback and advice (speed-mentoring) from a panel of experts.

**AWARD CEREMONY** 29<sup>th</sup> Nov. 3.30 pm | INNOV' AREA EXHIBITION HALL

The most innovative start-up will be rewarded  
on Day 2 of BioFIT at 3.30 pm in the INNOV' AREA  
in the exhibition hall.





DISCOVER THE MOST INNOVATIVE START-UPS IN THE FOLLOWING FIELDS:

## 20 start-ups, 1 prize



VASCULAR/METABOLIC

Op2Lysis  
Cardior Pharmaceuticals  
Emosis  
AptamiR Therapeutics



ONCOLOGY/  
IMMUNO-ONCO

STipe Therapeutics  
Theranovir  
Elthera  
ChromaLys



RESEARCH TOOLS/  
THERAPEUTIC  
DELIVERY

Mecachips  
DyNABind  
SimplicityBio  
Renovos



VACCINOLOGY /  
VIROLOGY

ViRelieve  
Vaxinano  
Par'Immune



AGEING / PAIN

Innopain  
PRAGMA Therapeutics  
Reminiscences

## PANEL OF EXPERTS:

### Maria Bobadilla

SENIOR DIRECTOR, EXTENDING  
INNOVATION NETWORK,  
ROCHE +

### Esther Lange

INDUSTRY LIAISON  
MANAGER, ASCENION 🇩🇪

### Garold Breit

DIRECTOR, TECHNOLOGY  
BUSINESS DEVELOPMENT,  
CITY OF CHARLESTON 🇺🇸

### Stephan Lensky

CHIEF OPERATING  
& CHIEF BUSINESS OFFICE,  
EPIMAB BIOTHERAPEUTICS +

### Florence Dal Degan

R&D INNOVATION  
SOURCING DIRECTOR,  
NOVO NORDISK +

### Cécile Theard-Jallu

PARTNER ATTORNEY,  
DE GAULLE FLEURANCE  
& ASSOCIÉS 🇫🇷

### Joel Yao

ASSOCIATE,  
SOFINNOVA PARTNERS 🇫🇷

### Christopher de Souza

DIRECTOR,  
BROADVIEW VENTURES 🇺🇸

# AGENDA | START-UP SLAMS

28<sup>th</sup> Nov. 2.30 > 4.00 pm | INNOV' AREA



## VASCULAR/ METABOLIC

### Op2Lysis

Intracerebral Haemorrhage (ICH) or haemorrhagic stroke | O2L-001, first medical treatment of ICH | Intracerebral thrombolysis with minimally invasive surgery

### Cardior Pharmaceuticals

Heart failure | Innovative RNA based therapeutics | Platform on noncoding RNA based therapeutics and diagnostics

### Emosis

In vitro diagnostics | Haemostasis | International

### AptamiR Therapeutics

Human obesity | Browning of adipocytes | MicroRNAs



## VACCINOLOGY/ VIROLOGY

### Vaxinano

Biotechnology | Nanoparticles | Vaccination

### ViRelieve

Human Respiratory Infectious (HRI) | Antivirals | Protein-protein interactions (PPIs)

### Par'Immune

Inflammation | Immunotherapy | Parasite subunit | Helminths



29<sup>th</sup> Nov. 9.00 > 10.30 am | INNOV' AREA



## ONCOLOGY/IMMUNO-ONCO

### STipe Therapeutics

Immune Oncology | Innate immune regulation | STING agonists

### Elthera

Oncology | Antibody therapy | Novel target

### Theranovir

Biomarkers | Anti-cancer antibodies | Anti-angiogenic and Checkpoint inhibitors

### Chromalys

Radiotherapy | Tumor labelling | Nano & micro technology

29<sup>th</sup> Nov. 2.00 > 3.30 pm | INNOV' AREA



## RESEARCH TOOLS/ THERAPEUTIC DELIVERY

### Mecachips

In vitro cell biology | Elastic and soft culture plates | Physiological in vitro cell culture

### DyNABind

Drug Discovery Technology | Small Molecule Drugs | Quality-controlled Libraries

### SimplicityBio

Biomarker discovery | Diagnostic - Dx | Companion diagnostics - CDx

### Renovos

Regenerative medicine | Orthopaedic biomaterials | Bone fracture healing



## AGEING/PAIN

### Innopain

Innovative Pharmacological Target | Protected NCEs | To replace opiates

### PRAGMA Therapeutics

Sensorineural Hearing loss | mGlu7 receptor modulator | Small molecule

### Reminiscences

Alzheimer's disease | Gut Microbiome | Therapeutic with companion diagnostic

# LICENSING OPPORTUNITY PRESENTATIONS

The Licensing Opportunity Presentations are presented by TTOs, universities or related structures that have ready-to-be-licensed technologies.

The aim of this session is to foster alliances and business development opportunities on innovative projects stemming from academia.

DISCOVER THE LATEST INNOVATIONS IN THE FOLLOWING FIELDS:



CANCEROLOGY



OSTEO-ARTICULAR



INFECTION /  
IMMUNOLOGY



DISCOVERY TOOLS /  
INFLAMMATION



NEUROLOGY



VASCULAR /  
METABOLIC

# AGENDA | LICENSING OPPORTUNITY PRESENTATIONS

28<sup>th</sup> Nov. 9.30 > 11.00 am | INNOV' AREA

**MODERATOR** **Shawn Manning** | CEO, AKESIOS ASSOCIATES 



## CANCEROLOGY

**Dermapol: Real time spectro-polarimetric optical biopsy**

Melanoma | Diagnosis  
Dermatology

**Bifunctional cyclam based ligands for conjugations with targeting vectors and their <sup>64</sup>-Cu radiopharmaceuticals for PET imaging**

Molecular imaging |  
Radiopharmaceuticals |  
Macrocyclic chelators

**New chemical entities activating the AMPK pathway for the treatment of melanoma and other solid tumors**

Melanoma | Cancer | Metformin

**Selective inhibitors of 17  $\beta$ -hydroxysteroid dehydrogenases**

Estrogen | Cancer | Endometriosis



## OSTEO-ARTICULAR

**Ultrasound-based Motion capture of bones**

Ultrasound-based motion capture |  
Quantitative analysis of walking |  
Prosthetic design, optimisation and  
evaluation

**S-Tronic Vertebro: Cement injection device for Vertebroplasty**

Remote control | Osteoporosis |  
Cement injection

**Implantable and nanoactive medical device for Osteo-articular regeneration**

Osteo-articular regeneration |  
Medical device | Combined  
Advanced Therapeutic Medicinal  
Product



## INFECTION/ IMMUNOLOGY

PCR Multiplex System for Fungal  
Diagnosis

PCR Multiplex | Fungal Infections |  
Diagnosis

SSC project - A preventive treatment  
for systemic sclerosis

Systemic sclerosis | Preventive  
treatment | Repurposing

Antiseptic, antithrombotic lock  
composition for catheters

Lock composition | Catheters |  
Antiseptic, antithrombotic solution

Leptospirosis rapid diagnostic test

Diagnosis | Leptospirosis | Sensitivity/  
sensitivity

TMB3 - Development of a new and  
innovative antibiotic agent

Antibacterial agent | Multi-resistance  
mechanisms countering | Nosocomial  
infections-MRSA/VRSA/VRE diseases



## DISCOVERY TOOLS / INFLAMMATION

Innovative Technology for in vivo  
Stabilization of Therapeutic Peptides

In vivo stabilization | Therapeutic  
peptides | Innovation

Production of cyclosporine-based  
micellar eye drops

Cyclosporin A | Eye drops |  
Ocular inflammation



## NEUROLOGY

Method for prediction of clinical response to VNS therapy in epileptic patients

Neurology | Epilepsy | VNS therapy

BR297:  
Preventive and curative treatment of chemotherapy-induced neuropathic pain

Neurosteroid | Chemotherapy-induced neuropathic pain | Neuroprotection

New method to induce reprogramming of somatic cells into cortico-spinal neurons

Cortico-spinal neurons | Cellular reprogramming | Neurodegenerative disease

Repurposing Citalopram for Treatment of Machado-Joseph Disease

Neurodegenerative diseases | Drug repurposing | Spinocerebellar ataxia type 3



## VASCULAR / METABOLIC

KABETE

Pancreatic islets | Type II diabetes | Regenerative Medicine

Shark - a suture-less vascular connector

Anastomosis connection tool | Surgical consumable | Time-saving

New biomarker for the prediction of the delayed brain stroke after subarachnoid haemorrhage

Brain Stroke | Predictive biomarker | Subarachnoid haemorrhage

Molecular diagnostics of genetic predisposition to acute coronary syndrome

Acute coronary syndrome | Predictive biomarker | Genetic susceptibility

## EXHIBITOR LIST

3M PURIFICATION..... B3  
ADIS..... F4

## AFSSI

ASSOCIATION FRANÇAISE  
DES SOCIÉTÉS DE SERVICES  
ET D'INNOVATION..... F1-E4  
CII/OA..... F1-E4  
DRUGABUS..... F1-E4  
ITEC SERVICES..... F1-E4  
RD-BIOTECH..... F1-E4  
SMALIS..... F1-E4

ALCAMI CORPORATION..... A1

## ALSACE BIOVALLEY

ALSACE BIOVALLEY..... E2-D8  
AÉRIAL..... E2-D8/1  
BIONEXT..... E2-D8/2  
CENTRE EUROPÉEN  
D'ÉTUDE DU DIABÈTE..... E2-D8/8  
CONFORMA FRANCE..... E2-D8/4  
DYNACURE..... E2-D8/6  
HARMONIC PHARMA..... E2-D8/7  
KSLINK..... E2-D8/9  
NANOTRANSMED..... E2-D8/3  
PHENOMIN-ICS..... E2-D8/5

ARTES BIOTECHNOLOGY..... F2  
ARVATO..... C8

## ATLANPOLE BIOTHERAPIES

ATLANPOLE BIOTHERAPIES D3  
BIOGENOUEST..... C11  
ID2SANTÉ..... D3

BACCINEX SA..... A2  
BACHEM..... C7

**MEDICALPS - THE HEALTH-  
-TECH CLUSTER OF THE  
FRENCH ALPS**

ARAYMONDLIFE..... D1-C9  
ECRINS THERAPEUTICS  
SERVICES..... D1-C9  
RHEONOVA..... D1-C9

MICROSYNTH AG..... B2  
NEURATRIS..... C3  
NOVA BIOMEDICAL..... A4  
OCR..... D9  
OVH DIGITAL LAUNCH PAD..... E1  
PHARMA LOGISTICS CLUB..... C12  
PRECI PLATFORM..... D9  
PORSOIT..... D4  
PROGINASE..... C2

## R&amp;D DATING FOR

**ANIMAL HEALTH AND  
INNOVATION - SIMV**

SIMV - FRENCH  
ASSOCIATION OF  
ANIMAL..... C13  
HEALTH INDUSTRY  
INSTITUT CARNOT FRANCE  
FUTURE ELEVAGE..... C14  
VET+ FOUNDATION,  
SPANISH TECHNOLOGY  
PLATFORM FOR ANIMAL  
HEALTH..... D5

## RÉSEAU SATT

AQUITAINE SCIENCE  
TRANSFER..... C6-B15  
AXIR..... C6-B15  
OUEST VALORISATION  
PULSAYS..... C6-B15  
RÉSEAU SATT..... C6-B15

SATT CONNECTUS..... C6-B15  
SATT GRAND CENTRE..... C6-B15  
SATT GRAND EST..... C6-B15  
SATT NORD..... C6-B15  
SATT SUD-EST..... C6-B15

SANTAKA VALLEY  
ASSOCIATION..... B9  
SCIENCE ME UP..... C10  
SCOMICS - ENABLING  
PRECISION MEDICINE..... C15  
SOLADIS..... B7  
SYNAGING SAS..... C4  
VEOLIA WATER  
TECHNOLOGIES..... D10  
VIROSCAN3D..... B1  
XPRESS BIOLOGICS..... B14

## INNOV' AREA

**VASCULAR | METABOLIC**

APTAMIR THERAPEUTICS..... I-A7  
CARDIOR..... I-A2  
PHARMACEUTICALS..... I-A6  
EMOSIS..... I-A1  
OP2LYSIS..... I-A1

## RESEARCH TOOLS

DYNABIND..... I-A5  
MECACHIPS..... I-A9  
RENOVOS..... I-A11  
SIMPLICITY BIO..... I-A10

## AGEING | PAIN

INNOPAIN..... I-A12  
PRAGMA  
THERAPEUTICS..... I-A16  
REMINI-  
SCIENCES..... I-A20

## VACCINOLOGY | VIROLOGY

PAR'IMMUNE..... I-A4  
VAXINANO..... I-A8  
VIRELIEVE..... I-A3

## ONCOLOGY | IMMUNO-ONCO

CHROMALYS..... I-A19  
ELITERA..... I-A15  
STIPE THERAPEUTICS..... I-A17  
THERANOVIR..... I-A18


## LILLE NORTHERN FRANCE

## BIOCLUSTER

EURASANTÉ..... D7  
NUTRITION HEALTH..... D7  
LONGEVITY CLUSTER..... E1-D7  
AMYGEN..... D7  
BOOST4HEALTH..... D7  
GENOSCREEN..... D7  
HCOS PHARMA..... D7  
INNOBIOCHIPS..... D7  
SENCEIT..... D7

MACO PHARMA..... D2  
MAGIE CHEMOSWED..... B5

# EXHIBITION PLAN



## 3M PURIFICATION

Website: [www.3m.com](http://www.3m.com)

3M Separation and Purification Sciences Division provides cutting edge separation and purification technology and products for biopharmaceutical companies involved in production of recombinant proteins, plasma fractionation products, vaccines and small molecule drugs. Using 3M's innovative material science platforms, we help companies optimize their processes, improve product safety and increase manufacturing efficiencies, thereby, improving lives everywhere as a trusted supplier of purification.

**B3**

## AÉRIAL

Website: [www.aerial-crt.com](http://www.aerial-crt.com)

Aérial, Technology Resource Centre, offers services in R&D in the freeze-drying and radiation processing. Aérial's freeze-drying activities encompasses thermal characterization, formulation and development of freeze-drying recipes for pharma products. In radiation processing, Aerial's services cover validation of radiation sterilization and dosimetry for medical devices and pharma products and assessment of the impact product attributes with regard to standards requirements.

**E2-D8/1**

## ADIS

Website: [www.springer.com/gp/adis](http://www.springer.com/gp/adis)

AdisInsight is a database to support decision making in drug research and development. It's based on scientifically sound data, assessed and summarized by expert scientists. A single search in AdisInsight is equivalent to searching thousands of other sources. AdisInsight allows you to quickly see the 'big picture' of a drug/disease landscape, interlinking

Scientific and commercial information on drugs

- ♦ Clinical trials
- ♦ Deals, acquisitions, collaborations
- ♦ Safety data

**F4**

## AFSSI

Website: [www.afssi.fr](http://www.afssi.fr)

The «Association Française des Sociétés de Services et d'Innovation (AFSSI)», French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners.

AFSSI represents over 130 companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs.

**F1-E4**



## **ALCAMI CORPORATION**

**A1**

Website: [www.alcaminow.com](http://www.alcaminow.com)

Alcami's cGMP drug product manufacturing facilities support preclinical, clinical and commercial supply. Our Charleston, South Carolina, is focused on processing parenteral products while the Wilmington, North Carolina facility is dedicated to solid oral dose manufacture. Both are fully integrated with Alcami's packaging and distribution center. Two cGMP API facilities in Germantown, Wisconsin and Weert, Netherlands support Alcami's process development/scale-up and clinical and commercial supply for customers worldwide.

## **AMYLGEN**

**D7/1**

Website: [www.amylgen.com](http://www.amylgen.com)

Amylgen is a preclinical CRO dedicated to provide our clients a comprehensive platform of models of neurodegenerative diseases/neurological disorders and techniques for the in vivo screening and pre-clinical validation of new drugs or nutraceuticals.

## **ALSACE BIOVALLEY**

**E2-D8**

Website: [www.alsace-biovalley.com/en](http://www.alsace-biovalley.com/en)

As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimize R&D development or business project in Europe, both in drug development and medical technologies. It is located in the famous French-German-Swiss BioValley with a unique concentration of international life sciences & healthcare players.

## **AQUITAINE SCIENCE TRANSFERT**

**C6-B15**

Website: [www.innovations-aquitaine.com](http://www.innovations-aquitaine.com)

Aquitaine Science Transfert is the Technology Transfer Office for the south west of France, covering 5500 researchers and 135 laboratories. We represent the regional academic research labs: Bordeaux University, INSERM, CNRS, Pau University, Bordeaux Polytechnic Institute, ... Since our creation in July 2012, we have signed 34 license agreements, patented 243 technologies and created 13 startups. Health, wellness and medical devices represent a key business in which our company is highly involved.

## ARAYMONDLIFE

D1-C9

Website: [www.araymond-life.com](http://www.araymond-life.com)

ARaymondLife is a French company, authorized as GMP EU pharmaceutical establishment since 2008, focused on the development and manufacture of solutions for the healthcare market. Specialized in plastic injection molding, ARaymondLife presents RayDylyo®, a RTU plastic push fit cap. Alternative to the aluminum cap, RayDylyo® is usable in isolators and RABS, for manual and automated capping. RayDylyo® exists in Ø20 and Ø 13mm, in bulk or nested, with or without the stopper pre-assembled in the cap.

## ARVATO

C8

Website: [www.arvato.com/en/industries/healthcare.html](http://www.arvato.com/en/industries/healthcare.html)

Healthcare systems, sales channels and distribution chains undergo constant changes to ensure patients derive the greatest benefit from innovative and existing pharmaceuticals and medical products at the most reasonable costs. Arvato Healthcare develop tailor-made outsourcing solutions that actively include all stakeholders within the healthcare sector - from patients, doctors and pharmacists through to health insurance companies and manufacturers.

## ARTES BIOTECHNOLOGY

F2

Website: [www.artes-biotechnology.com](http://www.artes-biotechnology.com)

Artes Biotechnology is a pharmaceutical contract research company specialized in microbial process development and technology transfer. We market the unique Metavax® (dHepB-VLP) technology in combination with yeast expression. This platform is applicable for large and multimeric antigens and able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization.

## ATLANPOLE BIOTHERAPIES

D3

Website: [www.atlanpolebiotherapies.com](http://www.atlanpolebiotherapies.com)

Atlanpole Biotherapies is truly involved in the medicine of tomorrow, with innovative areas of focus for the development of new therapies and the discovery of unexplored methodologies for human treatments. The projects of network, both academic and industrial, show the excellence of our expertise in personalized medicine.

It is a European Center Of Excellence in 4 domains:

- ♦ Immunobiotherapies
- ♦ Regenerative Medicine
- ♦ Radiopharmaceuticals
- ♦ Innovative technologies for biotherapies

**AXLR**

Website: [www.axlr.com](http://www.axlr.com)

AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France's Mediterranean area in Occitanie, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers.

**C6-B15****BACHEM****C7**

Website: [www.bachem.com](http://www.bachem.com)

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a comprehensive catalog of biochemicals available from stock and exclusive custom syntheses for research labs. A full range of services to the pharma and biotech industries complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach and towards its customers, Bachem shows total commitment to quality, innovation and partnership.

**BACCINEX SA****A2****BIOGENOUEST****C11**

Website: [www.baccinex.com](http://www.baccinex.com)

Baccinex is the preferential and highly recognized one-stop Swiss partner (CMO) for contract manufacturing of sterile lyophilized and liquid dosage forms. We routinely supply clinical medication for phase I, II and III trials to our (bio)pharmaceutical clients.

We offer a complete service including:

- ♦ Liquid or lyophilized drug product manufacturing (under aseptic conditions, in vials or ampoules)
- ♦ Secondary packaging (randomized labeling included)
- ♦ QC analytics (physicochemical and microb).

Website: [www.biogenouest.org](http://www.biogenouest.org)

Supporting research in life and environmental sciences. Biogenouest is a Scientific Interest Group founded by : Anses, CNRS, Ifremer, Inra, Inria, Inserm, Univ. Angers, Univ. Bretagne Occ., Univ. Bretagne Sud, Univ. Nantes, Univ. Rennes]. Ministry of Research Approved. Our network brings 34 technology core facilities that deliver hands-on solutions for labs and businesses across: genomics, proteomics, functional exploration, bioimaging structural and metabolic analysis, bioinformatics.

## BIONEXT

E2-D8/2

Website: [www.bionext.com](http://www.bionext.com)

Did you know: 85% of clinical failures are of biological origin and attributable to secondary targets? Classical in-silico approaches focus on the relationship between a pharmaceutical candidate and its target, but do not consider secondary interactions.

Bionext helps decipher and identifies such secondary targets based on structural knowledge of one of them within any kind of ligand-target (protein, RNA/DNA) interaction. Select the best drug candidates or repurposing possibilities, use BioSigh.

## BOOST4HEALTH

D7/3

Website: [www.boost4health.eu](http://www.boost4health.eu)

Boost4Health provides practical and financial support to life sciences companies who wish to explore their international growth potential.

11 leading business support organisations in 7 countries across Europe have joined forces into Boost4Health project to help SME to accelerate their international growth. By sharing expertise and networks, and providing practical and financial support, the Boost4Health community helps businesses to expand into new markets within North West Europe.

## BIOTRIAL

F3

Website: [www.biotrial.com](http://www.biotrial.com)

Biotrial, leading early phase CRO, provides solutions in early development from non-clinical to phase II studies. Based in France, London, Montréal and New York, Biotrial offers tailor-made solutions for the pharmaceutical and biotech industries. Available as stand-alone or full packages, Biotrial's services line includes: Non-clinical pharmacology, Regulatory Affairs, Phase I & II Study Management, Biometrics and Medical Writing, Monitoring, Core Lab, Bioanalysis, Pharmacovigilance.

## CELL&CO BIOSERVICES

A8

Website: [www.cell-and-co.com](http://www.cell-and-co.com)

Cell&Co BioServices offers a complete one-stop-shop solution for managing biological and clinical.

The services we offer cover the following activities:

- ♦ Biobanking
  - ♦ GMP Biorepository
  - ♦ Sample processing (extraction, aliquoting, fractionation, etc.) and bioanalysis
  - ♦ Sampling kit design, production and supply;
- Cell&Co is certified ISO 9001 and NF S 96-900 and also applies the following quality standards GMP, GLP, GCP and BPR (Best Practices for Repositories).

## **CENTRE EUROPÉEN D'ÉTUDE DU DIABÈTE**

**E2-D8/8**

Website: [www.ceed-diabete.org](http://www.ceed-diabete.org)

Created in 1991, the «Centre européen d'étude du Diabète» is a private translational diabetes research institute, encouraging active collaborations between clinicians and researchers, in order to develop innovative therapeutic strategies and therefor improve the patients' daily life. From its original status, the structure is a strong partner in the Scientific European community and acquired a rich portfolio of national and international collaborations from both academic and non-academic sectors.

## **CILOA**

**F1-E4/3**

Website: [www.ciloa.fr](http://www.ciloa.fr)

Based on its disruptive technology, Ciloa helps to develop therapeutic monoclonal antibodies and vaccines. Ciloa sorts monomers, homo- or hetero-oligomers of fully native membrane proteins (GPCRs, Ion channels, Kinase receptors, viral Env proteins...) on recombinant exosomes. This tool unlocks several steps of mAb development against membrane proteins, like:

- obtaining fully native antigen,
- immunization against poor immunogens,
- robust ELISA screenings,
- easy SPR characterization.

## **CIDETEC NANOMEDICINE**

**B6**

Website: [www.cidetec.es/en/nanomedicine](http://www.cidetec.es/en/nanomedicine)

Cidetec Nanomedicine is an institute for applied research that develops cutting-edge technology to transform it into advanced products.

Four pillars support this activity:

- ♦ Expert in technology transfer.
- ♦ Strategic collaborations,
- ♦ Differentiating facilities for the translation of nanomedicine

- ♦ Direct contact with the industry and clinicians

Our research is focused in:

- ♦ Drug-delivery via inhalation
- ♦ Drug-delivery via skin
- ♦ GMP Manufacturing of investigational medicinal products.

## **CITOLAB**

**E5**

Website: [www.citoxlab.com](http://www.citoxlab.com)

With facilities located in France, Canada, Denmark and Hungary, CiToxLAB offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, chemical, agrochemical and cosmetics companies worldwide.

CiToxLAB performs studies in general and reproductive toxicology, carcinogenicity, immunology, safety pharmacology, DMPK and bioanalysis. The group has unique expertise in areas such as inhalation, medical device, in vitro and environmental sciences.

## CONFARMA

E2-D8/4

Website [www.confarma.fr](http://www.confarma.fr)

Confarma is an analytical service provider for pharmaceutical, biotechnology, medical device, chemical and cosmetic industries. CONFARMA go with you for your methods development, validations and routine analysis in microbiology, biology and physico-chemistry, according to the highest standards. The site is a pharmaceutical establishment authorized by ANSM and declared compliant with GMP and GLP principles. Confarma is ISO 9001, 14001, OHSAS 18001, ISO 17025 accredited by COFRAC and FDA.

## CZECHINVEST

E3

Website: [www.czechinvest.org](http://www.czechinvest.org)

CzechInvest, the investment and business development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages overseas companies to look at the Czech Republic as their partner of choice. The agency helps its Czech and international customers by providing services that range from information provision and consultancy to implementation of business development programmes.

## CYTENA GMBH

E6

Website: [www.cytena.com](http://www.cytena.com)

Cytena's single-cell printer uses an imaging system and object recognition algorithms to detect cells in a single-use dispenser cartridge. Droplets are produced similar to inkjet printing. Cells are classified in the nozzle and subsequently dispensed directly into well plates. High viability has been observed for several cell lines.

## DELPHARM BIOTECH

B8

Website: [www.delpharm.com](http://www.delpharm.com)

You have identified reliable biomarkers or designed mAb against a bio-target.  
You have developed a companion diagnostic tool: immuno assay prototype (ELISA or LFIA) for biomarkers monitoring and you are willing to find a partner to industrialize your device before commercial batch.  
Delpharm Biotech, as Immuno Assay contract manufacturing organization (CMO) with all the capabilities, under ISO 13485 can meet your requirements in both veterinary and human diagnostic markets.

## DOMAINEX

A6

Website: [www.domainex.co.uk](http://www.domainex.co.uk)

Domainex is an integrated drug discovery service company serving pharmaceutical, biotechnology, academic and patient foundations globally. Domainex provides highly efficient scientific solutions to enable successful drug discovery programmes against a wide range of targets. Our highly experienced molecular biologists, medicinal, computation and analytical chemists have a strong success record in drug discovery, delivering on average one candidate drug every year for the past six years.

## DYNACURE

E2-D8/6

Website: [www.dynacure.fr](http://www.dynacure.fr)

Dynacure is a biotechnology company founded in 2016 that is developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare debilitating disease affecting children and young adults. Dynacure's Dyn101 is an antisense oligonucleotide developed in collaboration with IONIS Pharma (USA).

## DRUGABILIS

F1-E4/4

Website: [www.drugabilis.com](http://www.drugabilis.com)

DRUGABILIS is an established CRO specialized in pharmaceutical drugability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimization (salts, polymorphs, cocrystals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal ...). We are also often engaged for trouble shooting studies on drug products facing unexplained performance issues.

## EATRIS

C3B

Website: [www.eatris.eu](http://www.eatris.eu)

EATRIS helps you de-risk and add value to your drug, vaccine or diagnostic development programme. We do this by providing fast, tailored access to clinical expertise and cutting-edge enabling technologies available within our 80 academic centres across Europe. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

## **ECRINS THERAPEUTICS SERVICES**

**D1-C9**

Website: [www.ecrins-therapeutics-services.com](http://www.ecrins-therapeutics-services.com)

We offer unique services in drug discovery: cytoskeleton-related products and services. These services are intended as important filters in drug discovery and allow de-risking early-stage projects particularly in the fields of oncology and neurodegenerative-diseases. Our scientific team is dedicated to provide you answers and save you time. We are also able to offer tailor made assays from in vitro biochemistry to cell biology, in order to fully satisfy our clients' needs.

## **E-PHY-SCIENCE**

**B13**

Website: [www.e-phy-science.com](http://www.e-phy-science.com)

E-Phy-Science is a service company providing a top level expertise in in vitro and in vivo electrophysiology in rodent.

Combining these two approaches, E-Phy-Science offers an 'a la carte' service which is based on reactivity and high precision.

With its in Vitro platform E-Phy-Science provides field or single cell recording from acute brain slices or cell culture. With our in vivo platform, we provide field, multiunit as well as single unit recordings in freely moving or anesthetized rodents.

## **ENTERPRISE LITHUANIA**

**B10**

Website: [www.enterpriselithuania.com/enlsb2018.com](http://www.enterpriselithuania.com/enlsb2018.com)

Enterprise Lithuania is a non-profit agency under Ministry of Economy established to promote entrepreneurship, support business development and foster export. Their mission is to support the establishment and development of competitive businesses in Lithuania and to foster the country's exports by facilitating cooperation with partners' networks and providing quality training, consultancy, market analysis, and business-partner search services.

## **ERDYN**

**B4**

Website: [www.erdyn.com](http://www.erdyn.com)

Erdyn is a pure player of innovation.

Erdyn is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation.

We offer support for:

- ♦ Set up and management of collaborative projects
- ♦ Innovation marketing and business development
- ♦ Technological and scientific states of the art Technology/opportunity scouting



## EU-JAPAN CENTRE FOR INDUSTRIAL COOPERATION

E7

Website: [www.eu-japan.eu](http://www.eu-japan.eu)

The EU-Japan Centre for Industrial Cooperation is a non-profit organisation between the European Commission and the Japanese Government.

The mission of the EU-Japan Centre for Industrial Cooperation is:

- ♦ to promote all forms of industrial, trade and investment cooperation between Japan and the EU
- ♦ to strengthen the technological capabilities and the competitiveness of the European and Japanese industrial systems.

## FGK CLINICAL RESEARCH GMBH

A5

Website: [www.fgk-cro.com](http://www.fgk-cro.com)

FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization with offices in Germany (HQ), Poland, Czech Republic, Hungary and UK. We provide full service for Phase I - IV clinical studies. Our international client base includes biotechnology, medical device, and pharmaceutical companies. We have all the knowledge and experience necessary to guide you through the clinical trial process, from planning and approval to the final report.

## EURASANTÉ

D7

Website: [www.lille.eurasante.com](http://www.lille.eurasante.com)

Eurasanté is an incubator, a technology transfer facilitator and a leading cluster in the fields of biotech, nutrition and healthcare in the Northern France region. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The regional network includes around 1,000 companies working in Life Sciences and Healthcare. It benefits from an exceptional location in the heart of Europe (near Paris, London and Brussels). The Life Sciences sector in the Northern France region gathers a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which already hosts 7 hospitals, 4 universities, 7 specialised schools, more than 150 companies and 50 laboratories.

## FINDMED

D6

Website: [www.findmed.fr](http://www.findmed.fr)

Findmed is a consortium of 12 Carnot institutes, which are French academic research institutions selected for their ability to set up research partnerships with the industry (from SMEs to international corporations). These institutes are devoted to health research (human or animal), as well as additional expertise in chemistry, formulation and data processing. The objective of Findmed is to facilitate the access of companies to their expertise and technological resources.

## **FUTURE WORLDS**

**B11**

Website: [www.futureworlds.com](http://www.futureworlds.com)

Future Worlds is a startup platform and business incubator championing the innovative commercial opportunities being developed by researchers and students at the University of Southampton.

## **GENOSCREEN**

**D7/4**

Website: [www.genoscreen.com](http://www.genoscreen.com)

GenoScreen is a French biotech company. Since 2001 GenoScreen offers innovative services and solutions that help public and private sector research groups to characterize and exploit DNA. GenoScreen works on all kinds of genomes and proposes cutting-edge technologies. Our innovation strategy has generated a stream of successful projects, including top-level expertise in the characterization of microorganisms. GenoScreen's research programs develop new applications in highly competitive fields.

## **GENOSAFE**

**B12**

Website: [www.genosafe.com/fr](http://www.genosafe.com/fr)

GenoSafe is an Unique Laboratory CRO for Gene & Cell Therapies development: at R&D, Preclinical and Clinical Development stage.

GenoSafe supports Gene and Cell Therapy product development to cure rare/degenerative diseases

- ♦ Preclinical samples analysis
- ♦ Patients samples analysis from Clinical Trial
- ♦ Immunology monitoring and ADA development

## **HARMONIC PHARMA**

**E2-D8/7**

Website: [www.harmonicpharma.com](http://www.harmonicpharma.com)

Harmonic Pharma has developed a unique Pharmacological Rediscovery© platform based on polypharmacology that consists in identifying the ensemble of biological targets linked to safe drugs in order to investigate their novel therapeutic applications. The company most advanced candidate HPH112 - developed in collaboration with Institut Curie - represents a promising drug candidate for a fast and de-risked clinical development in combination with the most recent treatments e.g. immunotherapy.

## HCS PHARMA

D7/6

## IFREMER

C1

Website: [www.hcs-pharma.com](http://www.hcs-pharma.com)

HCS Pharma is a CRO specialized in cell imaging (HCA/HCS) that offers services (phenotypic screening, efficacy and safety assays, POC) in pre-clinical in vitro research. Expertise: the development of new in vitro tests in pharmacology and their use in medium / high throughput screening in cell imaging: «High Content Analysis» (HCA) / «High Content Screening» (HCS). Its areas of expertise: neurodegenerative diseases (Parkinson, Alzheimer, ...), oncology, toxicology (hepatotoxicology ...).

Website: [www.ifremer.fr](http://www.ifremer.fr)

Created by decree in 1984, the French Research Institute for Exploitation of the Sea is a public institute of industrial and commercial nature. Through studies and expert assessments, Ifremer contributes to knowledge about the oceans and their resources, the monitoring of marine and coastal zones and the sustainable development of maritime activities.

## ID2SANTÉ

D3

## INFICURE BIO

E8

Website: [www.id2sante.fr](http://www.id2sante.fr)

ID2Santé is a technology innovation centre operating in the Bretagne region (Western France). It is also the regional representative of the Atlanpole Biotherapies competitiveness cluster.

It is in close contact with regional researchers and companies from the health sector and helps forge partnerships to support R&D projects and to develop innovative health products.

Website: [www.inficurebio.com](http://www.inficurebio.com)

InfiCure Bio has developed a new and unique pre-clinical mouse model, the N-IF mouse, which spontaneously develops fibrosis in multiple organs.

We offer expert led, tailored, high-quality drug validation services for R&D companies and CRO's.

Our unique model offers extraordinary research advantages; is 100 percent reproducible, has a pathological progress similar to humans and displays a fibrosis preceded by inflammation.

Inficure Bio will break the status quo in anti-fibrotic drug development.

## **INNObIOCHIPS**

**D7/2**

Website: [www.innobiochips.fr](http://www.innobiochips.fr)

Innobiochips is a diagnostic company committed to propose innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and Immunodeficiency and is partnering with several major players which decided to incorporate the technology in larger IVD application.

Innobiochips is seeking other partners with a «SirYus inside» interest.

## **INSTITUT CARNOT FRANCE FUTUR ELEVAGE**

**C14**

Website: [www.francefuturelevage.com](http://www.francefuturelevage.com)

Carnot Institute Livestock Industry for the Future provides R&D competences to livestock sector businesses, mobilizing three main levers for multiefficient, sustainable and profitable farming: health, nutrition and breeding systems and animal genetics.

We brings together french actors from agro-veterinary research with an international visibility and R&D knowledge and expertise of three Agricultural Technical Institutes which are international leaders in the breeding services.

## **INOVIEM SCIENTIFIC**

**A3**

Website: [www.inoviem.com](http://www.inoviem.com)

Inoviem Scientific is a Contract Research Biotech (CRB) with unique label-free technologies for the identification of clinical target(s) directly from patient samples. We currently work with big, mid and small pharma companies all over the world.

Based on our two proprietary technologies, we aim to bring the relevant information on drug's efficacy, toxicity and molecular mechanism of action, from human tissues, as early as possible to enable the pharmaceutical industry to move forward.

## **ITEC SERVICES**

**F1-E4/5**

Website: [www.itecservices.com](http://www.itecservices.com)

Since 1984, ITEC Services perform clinical trials for pharmaceutical, biotechnological and medical device companies: study management, regulatory management, site selection, monitoring (on site / Remote monitoring), vigilance, data-management, statistics, medical writing.

ITEC Services has been certified ISO 9001 since 1997 (version 2015) and complies with the ISO 27001.

International Business Developer: [mathieu.caperaa@itecservices.com](mailto:mathieu.caperaa@itecservices.com)

CEO: [nathalie.dubon@itecservices.com](mailto:nathalie.dubon@itecservices.com)

## KITOS BIOTECH, SRLS

A7

Website: [www.kitosbiotech.org](http://www.kitosbiotech.org)

Kitos Biotech provides cell-based assay services for anticancer drug discovery research, taking advantage of cutting-edge automation systems. Kitos Biotech is an Italian private company founded in 2016 by two researchers in cancer cell and molecular biology. The laboratory is located in the scientific park of Porto Conte Ricerche (Italy).

## MACO PHARMA

D2

Website: [www.macopharma.com](http://www.macopharma.com)

Maco Pharma is one of the key players in the medical device industry for blood transfusion, solution bags and biotherapy. Their growth has always been driven by major innovations. These innovations are the result of substantial investments in research and development, as well as cooperation with customers and partners: blood centres, research laboratories, hospitals... For each of these 3 fields, Maco Pharma offers a range of products and services for each step of the processes. With 2300 employees, 4 plants (2 in France, 1 in Poland and 1 in Tunisia) and worldwide presence in nearly 100 countries, Maco Pharma aims at offering innovative solutions and quality products to optimise therapeutic practices and make them safer.

## KSILINK

E2-D8/9

Website: [www.ksilink.com](http://www.ksilink.com)

Ksilink's expertise lies in patient based, target free phenotypic drug discovery and preclinical development up to in vivo POC. Our ambition is to find new treatment solutions in the areas of muscular and cardiovascular diseases, neurodegenerative and psychiatric diseases. Ksilink further has launched several oncology and immune oncology projects. Ksilink acts like a highly specialized open innovation center enabling technology transfer for academic and biotech partners.

## MAGLE CHEMOSWED

B5

Website: [www.maglechemoswed.com](http://www.maglechemoswed.com)

Our Mission: We create innovative solutions to healthcare challenges.

Our vision: We combine our unique knowledge of formulating delivery systems and our drug development expertise to bring innovations from idea to Product.

We pride ourselves in coming up with elegant solutions to healthcare challenges. Whether it be developing unique products of our own or applying our expertise to advance our customers' production processes, creativity is one of our core values.

## **MICROSYNTH AG**

Website: [www.microsynth.ch](http://www.microsynth.ch)

As a private and independent Swiss company, Microsynth provides services related to DNA/RNA synthesis, various kinds of DNA/RNA analyses and molecular biology project outsourcing. For more than two decades, our objective has been to serve our customers by delivering products and services of the highest quality, on time and with outstanding service – and all this at competitive prices.

**B2**

## **NEURATRIS**

Website: [www.neuratris.com](http://www.neuratris.com)

NeurATRIS is a research infrastructure conceived to accelerate the translation of discoveries in basic research into medical innovations for the treatment of diseases of the nervous system.

NeurATRIS brings together the biggest French teams of experts such as 5 hospitals and public research institutes whose expertise and skills in neuroimaging, pharmacology and biotherapies are complementary and internationally recognized.

NeurATRIS is the French node of EATRIS-ERIC.

**C3**

## **NANOTRANSMED**

Website: [www.nanotransmed.eu](http://www.nanotransmed.eu)

Nanotransmed enables french, german and swiss scientists to develop together applications and innovations in nanomedicine, meeting major issues regarding patients' care. The consortium focuses in particular on issues concerning early, reliable and fast diagnosis but also personalized treatment of diseases such as cancers and inflammation as well as issues regarding nosocomial infections contracted by 5% of hospitalized patients. The project is cofinanced by the Interreg VA Upper Rhine programme.

**E2-D8/3**

## **NOVA BIOMEDICAL**

Website: [www.novabio.us/fr](http://www.novabio.us/fr)

Nova manufactures automated analyzers for cell culture and fermentation monitoring. Our modular BioProfile FLEX provides key chemistries and gasses and is expandable to include Cell Density and Cell Viability, Osmolality and IgG or Phosphate results with the same sample and a single data output stream. BioProfile CDV is an automated cell density/viability analyzer with a range of up to 80 million cells/mL. Stat Profile Prime is a compact high throughput, low sample volume, 9-test chemistry/gas analyzer with no maintenance cartridge technology.

**A4**

## **NUTRITION HEALTH LONGEVITY CLUSTER**

**D7**

Website: [www.nhl-cluster.com](http://www.nhl-cluster.com)

The NHL Cluster is the only French cluster to combine Nutrition, Biotechnology and Health. The NHL Cluster focuses on the fields of prevention and treatment of life-style related diseases. We identify opportunities (technology, market, product, financial aid), we facilitate exchange between potential and existing members, we contribute to collaborative R&D projects between academia, national and international public research institutions and private companies. NHL Cluster, Your Innovation Partner.

## **OUEST VALORISATION**

**C6-B15**

Website: [www.ouest-valorisation.fr](http://www.ouest-valorisation.fr)

Ouest Valorisation – Office of Technology Transfer (OTT) was created in the «Future Investments» project call managed by Ministry of Higher Education and Research. It aims to propose to companies attractive innovation means from the public research. Ouest Valorisation's team simplifies the access of the companies to research laboratories in order to develop good collaborative projects or to get access to high professional skills and high level scientific equipment.

## **OCR**

**D9**

Website: [www.oncovet-clinical-research.com](http://www.oncovet-clinical-research.com)

OCR is focused on comparative medicine studies of dogs with spontaneous cancers and chronic diseases, as natural animal models for assessment of drug candidates under development for Human. OCR provides to Biotech-Pharma-MedTech companies more predictive data of human diseases for a more relevant development in clinic. OCR also acts as a full vet-CRO for pilot and pivotal studies for the Vet market. OCR benefits from an internal histology/IHC platform and a canine and feline tumor biobank.

## **OVH DIGITAL LAUNCH PAD**

**E1**

Website: [www.ovh.com/dlp](http://www.ovh.com/dlp)

OVH Digital Launch Pad is the startup support program of OVH, Europe's largest cloud provider. It provides innovative startups with funding and technical support from seed stage to market. Via the Digital Launch Pad, OVH will support companies with training, logistics and marketing as well as access to exclusive events and OVH's cloud infrastructure. Startups receive this assistance from early-stage until they are ready to launch publicly.

## PHARMA LOGISTICS CLUB

C12

Website: [www.pharmalogistics.club](http://www.pharmalogistics.club)

The Pharma Logistics Club (PLC) is a non-profit inter-professional association, to intellectual vocation, managed by professionals belonging to health establishments and providers from all sectors, without distinction of specialties in the field of Supply Chain Pharmaceutical. Its purpose is to bring together people interested in participating to a better understanding and improvement of GDP and awareness for biotechs, CRO and research institutes. International positioning, we offer conferences, technical committees, logistics site visits and online tools.

## PORSOLT

D4

Website: [www.porsolt.com](http://www.porsolt.com)

Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission.

Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

## PHENOMIN-ICS

E2-D8/5

Website: [www.phenomin.fr](http://www.phenomin.fr)  
[www.ics-mci.fr](http://www.ics-mci.fr)

Phenomin-ICS is a research infrastructure of excellence for translational research and functional genomics. It provides a comprehensive set of specialized services to academic and industrial users and is a major player in the European post-genomics area programs.

It ensures the generation and validation of mutant mouse and rat models «à la carte», as well as phenotypic analysis and preclinical studies covering the major physiological systems to better understand gene function and human disease.

## PRECI PLATFORM

D9

Website: [www.plateforme-prec.com](http://www.plateforme-prec.com)

Since 2015, PRECI provides to Biotech-Pharma clients experimental irradiation (Megavoltage Unit - Elekta Precise) & imaging platform (CT-scan, MRI, Scintigraphy) applied to preclinical protocols (mice and rats, pigs, sheep, rabbits). PRECI also provides Histology/IHC services (VIP, embedding, microtomy, imaging tissue, specific staining - automated slide stainer - lesion scoring, morphometric analysis and immunohistochemical staining via Ventana Discovery XT).



## PROQINASE

C2

F1-E4/1

Website: [www.proqinase.com](http://www.proqinase.com)

ProQinase is a preclinical CRO dedicated to support the development of cancer therapeutics by providing customized solutions that cover the full range of services from hit identification to preclinical testing. ProQinase's portfolio includes biochemical kinase assays, cell-based assays, and in vivo tumor models. We continuously work to extend these services and, in addition, offers custom-tailored assay development to provide state-of-the-art drug discovery service.

## RD-BIOTECH

Website: [www.rd-biotech.com](http://www.rd-biotech.com)

RD-Biotech is a French CRO offering a wide range of services and products in Biotechnology:

- ♦ Bioproduction & purification: Monoclonal antibodies (murine, rat, chimeric, humanized), Recombinant proteins, Plasmids, cells
- ♦ R&D contracts: Hybridoma development, transfection and cell lines development, Cloning and vector construction, Chimeric and humanized antibodies...

♦ Analytical services: Immunoassays, OCTET, bioassays platform...

FastELISA kits: Ig G quantification (mouse, human, rat).

## PULSALYS

C6-B15

## RÉSEAU SATT

C6-B15

Website: [www.pulsalys.fr](http://www.pulsalys.fr)

Pulsalys is a French Technology Transfer Office (TTO), created in 2013 with a public funding of 57 M€, committed in detecting high-potential research results from the laboratories of Lyon & St Etienne, and turning them into strong innovations for companies, or into high tech startup businesses.

Website: [www.sattf.fr](http://www.sattf.fr)

In France, SATTs have the challenging mission to accelerate the transformation of French research into innovations. Their aim is to enhance the value and to accelerate the process of technology transfer from publically funded research toward industry. SATTs evaluate, market and license technology from French Universities and Public Research Organisations.

SATTs have become a major actor of economic development to reinforce company competitiveness, with an emphasis on SMEs and start-ups.

## **RHEONOVA**

**D1-C9**

Website: [www.rheonova-medical.com](http://www.rheonova-medical.com)

Rheonova offers a new physical biomarker for drug discovery and efficacy evaluation. Our product Rheomuco and the associated services aim to provide new pharmacodynamic data during in vitro studies or clinical trials in the fields of pulmonary diseases (cystic fibrosis, COPD, asthma...). Our technology measures the viscoelasticity of mucus and deliver the physical properties of bronchial secretions. The benchmark of new molecules is performed using patient sputum or mucus obtained by cell culture.

## **SATT CONECTUS**

**C6-B15**

Website: [www.conectus.fr](http://www.conectus.fr)

SATT Conectus Alsace is the single entry point for companies and exclusive business partner to access all the innovations originating from public research institutions in Alsace, one of the top ranked regions in France for the excellence of research. It is also the partner of choice to access a unique and broad range of highly advanced knowhows, skills and facilities, within a favourable geographic position in the heart of Europe (Alsace borders Germany and Switzerland).

## **SANTAKA VALLEY ASSOCIATION**

**B9**

Website: [www.santakosslenis.lt](http://www.santakosslenis.lt)

Association Santakos Slėnis (Santaka Valley) unites and integrates activities of 4 largest research and study institutions of Kaunas : Kaunas University of Technology, Lithuanian University of Health Sciences, Vytautas Magnus University and Lithuanian Energy Institute at the science and business valley «Santaka». The aim of association is to carry out interdisciplinary scientific and applied research, to create proper conditions for high-quality research services to businesses, to coordinate.

## **SATT GRAND CENTRE**

**C6-B15**

Website: [www.sattgc.com](http://www.sattgc.com)

SATT Technology Transfer Organization (Center of France) organizes early detection of inventions and guarantees its exclusivity.

SATT Center of France reveals the potential of future innovations for a successful transfer to business in providing financial and technical supports.

Located in Clermont-Ferrand, SATT Center of France works with 6 Universities, 3 Regions, 8 Institutes of Technology and 8500 Researchers and Professors.

## **SATT GRAND EST**

**C6-B15**

Website: [www.sattge.fr](http://www.sattge.fr)

SATT Grand Est is a French governmental TTO. Our role is to identify and invest into R&D projects from French public research laboratories and transfer the resulting innovation to the industry. The scope of our activity includes: healthcare, material sciences, chemical processes, software. We also provide technical and scientific services under the trademark «Welience». Those services include genomics, lipidomics, imaging, cytometry, histology, protein engineering, bioinformatics, etc.

## **SATT SUD-EST**

**C6-B15**

Website: [www.sattse.com](http://www.sattse.com)

Satt Sud Est is a private Technology Transfer Organization (TTO) with exclusive rights to source, protect, develop and license the results of research from public laboratories in the Provence-Alpes-Côte d'Azur (PACA) and Corsica french Regions. Its goal is to help companies acquire reliable technologies that are better suited to the industrial challenges they face.

## **SATT NORD**

**C6-B15**

Website: [www.sattnord.fr](http://www.sattnord.fr)

SATT Nord is a growth-generating tool for valorisation serving researchers and responding to the economic and societal needs for technology transfer.

Thanks to a multidisciplinary team of professionals (experts in the various fields of research, project managers, experts in intellectual property, legal experts), SATT Nord ensures the detection of projects, their maturation and the protection of the intellectual rights and even up to their commercialisation through transfer.

## **SCIENCE ME UP**

**C10**

Website: [www.sciencemeup.com](http://www.sciencemeup.com)

Each and every project, concept or specific need is like a rocket ready to be launched. You are the captain of the spaceship and you must fulfill your mission. We are a specialized service provider in Research and Development. Whether you plan to conquer space or develop your business, our team will support your endeavours. Whatever your request, we can offer a scientific expert for service provision, event planning, recruitment, and training that will come on board to fulfill your mission.

## SCIOMICS - ENABLING PRECISION MEDICINE

Website: [www.sciomics.de](http://www.sciomics.de)

Sciomics established a broad biomarker development pipeline for oncological indications as well as organ failure. The underlying scioDiscover platform combines a broad coverage of more than 1000 proteins including their phosphorylation status with all advantages of classical immunoassays.

Plasma, tissue, cell samples, and cerebrospinal fluid from human, mice and rat can be analysed to identify biomarkers, elucidate disease mechanisms or obtain an in-depth understanding of the underlying biology.

C15

## SIMV - FRENCH ASSOCIATION OF ANIMAL HEALTH INDUSTRY

C13

Website: [www.simv.org](http://www.simv.org)

The French association for animal health industry (SIMV) represents and federates 39 manufacturers and marketers on the French market of medicines and reagents for pets and for farm animals.

## SENCET

Website: [www.sencet.fr](http://www.sencet.fr)

Sencet is a spin-off from the CNRS and relies on a bio-technologie, the Silicon Nanotweezer (SNT). The concept is based on the use of microtechnologies to measure the electrical and mechanical properties of individual cells. This type of measurement has been shown to allow the differentiation of normal and cancer cells. In the short term, Sencet products will take place in academic laboratory environment as powerful cell characterization tools. And in the middle term, Sencet will provide diagnosis tools for early detection of cancer from blood sample.

D7/5

## SMALTIS

F1-E4/2

Website: [www.smaltis.fr](http://www.smaltis.fr)

The SMALTIS compagny, specialized in biotechnologies, designs through contracted services, customized solutions in Microbiology and Molecular Biology to help laboratories with their R&D projects. Its strength relies on a qualified team with specific know-how and an ISO 9001 certification in order to provide a personalized, confidential, interactive and quality service. With a solid scientific background and a diversified and certified «toolbox», SMALTIS operates globally in R&D projects.

## SOLADIS

B7

Website: [www.soladis.fr](http://www.soladis.fr)

Soladis is a consulting and service company specialized in data. To answer requests of data collection, analysis, and valorization, Soladis developed dedicated expertise:

- ♦ Soladis Connect, specialized in data collection through IoT, sensors and biosensors
- ♦ Soladis Statistics, to define statistical methodologies, and execute data analysis
- ♦ Soladis Digital, taking care of data science or big data projects
- ♦ Soladis Clinical Studies, full-services CRO, taking care of all or parts of clinical studies from protocol writing to publication thanks to a medical expertise.

## VEOLIA WATER TECHNOLOGIES

D10

Website: [www.veoliawatersti.com](http://www.veoliawatersti.com)

Veolia Water Technologies, the expert in water cycles, provides specialist equipment for the production and supply of water to industrial companies and laboratories, in compliance with the most stringent quality of water.

Our range of Elga Veolia equipment meets all laboratory water production needs, from ultra pure water to the production of purified water for general use.

## SYNAGING SAS

C4

Website: [www.synaging.com](http://www.synaging.com)

SynAging focuses on disease-inducing misfolded protein aggregates. Advances in neurobiology helped to understand the pivotal role of soluble prion-like misfolded protein aggregates in neurodegenerative diseases. SynAging has proprietary procedures to create aggregates with highest reproducibility. Oligomers are used in vitro and in vivo to induce neurodegeneration acutely and provide drug developers with fast access to phenotypic models mimicking the corresponding neurodegenerative disease.

## VET+I FOUNDATION, SPANISH TECHNOLOGY PLATFORM FOR ANIMAL HEALTH

D5

Website: [www.vetmasi.es](http://www.vetmasi.es)

Vet+i Foundation is an interdisciplinary forum that integrates all relevant stakeholders from academia, research, farmers, veterinarians, industry, regulators, etc. interested in animal health in Spain.

Vet+i has been created to improve R&D in the field of animal health.

Goal: to facilitate networking and discussion in order to achieve its main goal: to enable the efficient transfer of research developed and accelerate the development and delivery of effective tools for control animal disease.

## **VIROSCAN3D**

**B1**

Website: [www.viroscan3D.com](http://www.viroscan3D.com)

ViroScan3D is a service provider company in «Genomics Analysis» for infectious diseases including Pathogen Discovery, Biomarker discovery and Biosafety. Based on a solid expertise in genomics, microgenomics, particularly in NGS and microarrays, we perform Transcriptome, Genome, Metagenome and Epigenome analysis as well as Sequencing of new virus, bacteria, fungi, viromes and microbiomes. Our services are complete, from data analysis and available from low-copy and low-integrity samples.

## **XPRESS BIOLOGICS**

**B14**

Website: [www.xpress-biologics.com](http://www.xpress-biologics.com)

Xpress Biologics is a contract development organization specialized in the production of Biologics, proteins and DNA, for the therapeutic and diagnostic markets. The production scale and the quality of the biologics (R&D and GLP) are adapted for in vitro and in vivo pre-clinical validation of the biologics.

Xpress Biologics processes take into account the industrial and regulatory requirements, which greatly facilitates the transfer of the project to CMOs for the production of GMP grade material.



## A BIOPHARMACEUTICAL GROUP COMMITTED TO THE LIFE

OF HUNDREDS OF THOUSANDS OF PATIENTS SUFFERING FROM SERIOUS AND OFTEN RARE DISEASES WHO ARE TREATED EACH YEAR WITH OUR BIOPHARMACEUTICALS.

The LFB Group specializes in biopharmaceuticals: plasma-derived medicinal products, recombinant proteins, monoclonal antibodies and advanced therapies.

The LFB Group manufactures its biological medicines in 5 bioproduction plants – 4 of which are in France – and markets its products in more than 40 countries.

[www.groupe-lfb.com](http://www.groupe-lfb.com)

Follow us on social networks



**MERCK**

## ACCELERATE ACCESS TO HEALTH for people everywhere.

Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community.



### GLOBAL

1 global force across 66 countries



### EXPERTISE


A wealth of experience in solving the toughest challenges



### COMPLETE

Enhanced tools, resources and customer service

Learn more at [merckgroup.com/en/expertise.html](http://merckgroup.com/en/expertise.html)



The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Copyright © 2017 Merck KGaA. All Rights Reserved. Merck and the Vibrant M are trademarks of Merck. All other trademarks are the property of their respective owners. 10/2017 2017 - 07570

# WIN A FULL PASS FOR THE NEXT EDITION!



**Biofit** FOSTERING INNOVATION & TRANSFER  
LILLE 2018 - FRANCE

Have a chance to win in three easy steps:

- 1 Take your picture in front of the BioFIT sponsor wall
- 2 Post it on Twitter with the hashtag: **#BioFIT2018**
- 3 Follow our account:  **@BIOFIT\_EVENT**

The draw will take place on 30<sup>th</sup> November 2017.  
The winner will be contacted by the BioFIT team.

## SPONSORSHIP OPPORTUNITIES



### FOR BioFIT 2018

No matter what is your business target, highlighting your visibility or connecting with key players, BioFIT has the sponsorship opportunity that suits your needs and your budget.

Here is an overview of the opportunities we can offer:

- ♦ Partnering opportunities
- ♦ Online, print and onsite visibility
- ♦ Specific sponsorship opportunities

To sponsor BioFIT next edition, on 4<sup>th</sup> and 5<sup>th</sup> December 2018 in Lille (France), please contact **Margaux Satola**: [msatola@eurasante.com](mailto:msatola@eurasante.com) | +33 (0)3 59 39 01 82



PALAIS DE LA MUSIQUE  
ET DES CONGRÈS



**Biofit**

FOSTERING  
INNOVATION  
& TRANSFER

STRASBOURG 2017 - FRANCE

COCKTAIL / NETWORKING / DANCING

# BioParty

28<sup>TH</sup>

NOVEMBER  
from 6.30 pm

FOLLOW THE RHYTHM AND ENJOY YOUR NETWORKING EVENING

FEATURING DJ  
VLADIMIR  
SPOUTNIK



Free for all BioFIT attendees

# The Best Antibody Discovery Technology Is Now at Your Fingertips



**TRIANNI**  
Exceptional Human Antibody Discovery

## Trianni Mouse Antibodies are a Match for Humans

The Trianni Mouse™ platform is the only transgenic antibody discovery platform ever developed that offers the entirety of human antibody variable gene diversity in a single organism.

The V-gene segments in The Trianni Mouse are chimeric, but the variable domains of antibodies made by the mouse are entirely human. The result is human antibody leads generated from antibody genes optimized for function in the mouse. Or, in the simplest terms, The Trianni Mouse is a more human mouse.

To learn more about this innovative platform and how it can help you leave your mark on therapeutic antibody discovery and development, visit **Trianni.com**.



CDR-H3 residue utilization in antibodies derived from human samples and the Trianni transgenic Ig Mouse. In the naive Trianni Mouse, heavy chain CDR3 (CDR-H3) aa utilization frequency is effectively the same in humans and in The Trianni Mouse.



*Lilly unites caring with discovery  
to make life better for people around the world*

Lilly France 24 boulevard Vital Bouhot  
CS 50004 - 92521 Neuilly sur Seine Cedex  
Tél. : 01 55 49 34 34 - Fax : 01 41 44 02 47  
www.lilly.fr - S.A.S. au capital de 375 713 701 €  
609 849 153 R.C.S. Nanterre

*Lilly*

# WITH THE SUPPORT OF

## GOLD SPONSOR



## BRONZE SPONSORS



## CONTRIBUTING SPONSORS



## SUPPORTERS



## MEDIA PARTNERS



## INSTITUTIONAL PARTNERS







# Save the Date

4<sup>th</sup> & 5<sup>th</sup>  
Dec. 2018

7<sup>th</sup>  
edition

LILLE,  
France



# Biofit

FOSTERING  
INNOVATION  
& TRANSFER

## LILLE 2018 - FRANCE

A 360° approach to source  
early-stage innovations in Life Sciences

Organised by  **eurasanté**  
Invest for Success



In collaboration with  **Alsace  
BioValley**

Contact: Margaux Satola  
[msatola@eurasante.com](mailto:msatola@eurasante.com)